Search results
Results from the WOW.Com Content Network
Novartis AG also held 33.3 percent of the shares of Roche until 2022, however it did not exercise control over Roche. [122] Novartis also has two significant license agreements with Genentech, a Roche subsidiary. [123] One agreement is for Lucentis; [124] the other is for Xolair. [125] [121]: 239
Swiss drugmaker Novartis (NOVN.S) is moving further into gene therapy by buying AveXis (AVXS.O) for $8.7 billion, adding a rare-disease treatment that could reap billions in sales. The $218-per ...
Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%. The Swiss group will ...
Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas , Texas , United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
(Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.
(Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic. [3] In 2017, NITD moved out of Singapore to be beside Novartis' infectious diseases research headquarters in Emeryville, California, United States. [4]